Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic Melanoma
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 14 Dec 2018 Planned End Date changed from 31 Dec 2032 to 31 Dec 2031.
- 14 Dec 2018 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2021.
- 14 Dec 2018 Status changed from not yet recruiting to recruiting.